<table width="75%" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col align="left" valign="top" width="50%"></col>
<col align="left" valign="top" width="50%"></col>
<tbody>
<tr stylecode="TopRule">
<td colspan="4">
<content stylecode="bold">I. </content> Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:</td>
</tr>
<tr>
<td rowspan="1" valign="top">DRUG</td>
<td>DESCRIPTION OF INTERACTION</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>Hypoglycemia potentiated.</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Decreases tubular reabsorption; clinical toxicity from methotrexate can result.</td>
</tr>
<tr>
<td>Oral Anticoagulants</td>
<td>Increased bleeding.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">II. </content> Drugs changing salicylate levels by altering renal tubular reabsorption:</td>
</tr>
<tr>
<td rowspan="1" valign="top">DRUG</td>
<td>DESCRIPTION OF INTERACTION</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Decreases plasma salicylate level; tapering doses of steroids may promote salicylism.</td>
</tr>
<tr>
<td>Acidifying Agents</td>
<td>Increases plasma salicylate levels.</td>
</tr>
<tr>
<td>Alkanizing Agents</td>
<td valign="middle">Decreased plasma salicylate levels.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">III. </content> Drugs with complicated interactions with salicylates:</td>
</tr>
<tr>
<td rowspan="1" valign="top">DRUG</td>
<td>DESCRIPTION OF INTERACTION</td>
</tr>
<tr>
<td>Heparin</td>
<td>Salicylate decreases platelet adhesiveness and interferes with hemostasis in heparin-treated patients.</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>Inhibits pyrazinamide-induced hyperuricemia.</td>
</tr>
<tr>
<td>Uricosuric Agents</td>
<td>Effect of probenemide, sulfinpyrazone and phenylbutazone inhibited.</td>
</tr>
<tr>
<td colspan="2">The following alterations of laboratory tests have been reported during salicylate therapy:</td>
</tr>
<tr>
<td rowspan="1" valign="top">LABORATORY TESTS</td>
<td>EFFECT OF SALICYLATES</td>
</tr>
<tr>
<td>Thyroid Function</td>
<td>Decreased PBI; increased t<sub>3</sub> uptake.</td>
</tr>
<tr>
<td>Urinary Sugar</td>
<td>False negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5g q.d.).</td>
</tr>
<tr>
<td>5-Hydroxyindole acetic acid</td>
<td>False negative with fluorometric test.</td>
</tr>
<tr>
<td>Acetone ketone bodies</td>
<td>False positive FeCI<sub>3</sub> in Gerhardt reaction; red color persists with boiling.</td>
</tr>
<tr>
<td>17-OH corticosteroids</td>
<td>False reduced values with &gt;4.8g q.d. salicylate.</td>
</tr>
<tr>
<td>Vanilmandelic acid</td>
<td>False reduced values.</td>
</tr>
<tr>
<td>Uric Acid</td>
<td>May increase or decrease depending on dose.</td>
</tr>
<tr stylecode="Botrule">
<td>Prothrombin</td>
<td>Decreased levels; slightly increased prothrombin time.</td>
</tr>
</tbody>
</table>